聚乙二醇干扰素联合恩替卡韦治疗慢性乙肝的临床分析  

Clinical Analysis of Pegylated Interferon Combined With Entecavir in the Treatment of Chronic Hepatitis B

作　　者：梁冰[1] 殷海燕 LIANG Bing;YIN Haiyan(Internal Medicine Department,Jilin Province Liver and Gallbladder Disease Hospital,Changchun Jilin 130062,China)

机构地区：[1]吉林省肝胆病医院内科,吉林长春130062

出　　处：《中国继续医学教育》2018年第29期133-135,共3页China Continuing Medical Education

摘　　要：目的探讨聚乙二醇干扰素联合恩替卡韦治疗慢性乙肝的临床效果。方法选取我院收治的140例进行研究,按照抛硬币法进行分组,对照组70例,采用单纯聚乙二醇干扰素治疗,观察组70例,采用聚乙二醇干扰素联合恩替卡韦治疗,比较两组的治疗效果。结果在临床总有效率方面,联合用药治疗的观察组效果更加理想,组间差异存在统计学意义(P <0.05);且治疗48周后,观察组患者的HBeAg转阴率、HBV-DNA转阴率、ALT复常率均明显高于对照组(P <0.05)。结论采用聚乙二醇干扰素联合恩替卡韦方式对慢性乙肝患者实施治疗效果显著,可改善患者病情。Objective To investigate the clinical effect of pegylated interferon combined with entecavir on chronic hepatitis B. Methods One hundred and forty patients admitted to our hospital were selected for study and grouped according to the coin toss method. Seventy patients in the control group were treated with pegylated interferon alone, and seventy patients in the observation group were treated with pegylated interferon combined with entecavir. The treatment effects of the two groups were compared. Results In terms of total clinical efficiency, the observation group of combined drug treatment was more effective and the diference between the groups was statistically signifcant （P 〈 0.05）;and after 48 weeks of treatment, the HBeAg negative rate and HBV-DNA of the observation group were observed. The negative rate and the ALT normalization rate were signifcantly higher than those in the control group （P 〈 0.05）. Conclusion The use of pegylated interferon combined with entecavir in the treatment of chronic hepatitis B patients has significant efect, can improve the patient＇s condition.

关 键 词：聚乙二醇干扰素 恩替卡韦 慢性乙肝 HBeAg转阴率 HBV-DNA转阴率 ALT复常率 

分 类 号：R453[医药卫生—治疗学]